Instead of a one-size-fits-all approach, biotech leaders should first identify their next logical investor. Then, they should tailor their clinical strategy and milestones to directly address the uncertainties that specific investor class needs resolved.

Rion structures itself as a central "hub" with core technology, then creates separate "spoke" companies for verticals like veterinary or cosmetics. These spokes raise their own targeted capital, allowing Rion to fund platform development without constant dilution at the parent company level and diversifying funding risk.

Andera Partners structures its single fund to include early (20%), mid (50%), and late-stage (30%) companies. This mixed-stage approach allows them to generate earlier liquidity from mature assets to satisfy investors (LPs), which in turn enables them to take long-term bets on nascent biotechs without needing separate, stage-specific funds.

Rahul Aras learned from his first venture that combining a novel target, a new modality (gene therapy), and a unique delivery device created too many unknowns. At Iterion, he prioritized minimizing such variables to create a more manageable risk profile for investors and partners, focusing on a single core innovation.

This structure offers fundraising flexibility by appealing to two distinct investor types. Some investors prefer the diversified, lower-risk profile of the central hub, while others want direct exposure to a specific high-potential asset or disease area within a subsidiary spoke. This broadens the potential capital pool.

The biotech venture model is built on syndication, not competition. As a drug progresses, capital requirements balloon to hundreds of millions for late-stage trials, far exceeding any single VC's capacity. This structural reality forces firms to co-invest and partner throughout a company's lifecycle.

To attract investment, founders must translate their science into a business case. This involves articulating the target customer, go-to-market strategy, cost structure, and value proposition. Investors back ventures that connect three key elements: strong science, a clear clinical need, and a credible business model.

Disruptive MedTech ideas attract investment, but they are high-risk. Founders should de-risk these big bets by developing market access and commercial strategies simultaneously with product development, not after FDA approval.

For ambitious projects like surgical robotics with long development timelines, relying solely on traditional VC is risky. RoboCath found that bringing in corporate investors provided a long-term strategic vision and reassured other shareholders, which is critical for survival.